



**SUPPLEMENTARY FIG. S6. Fenofibrate ameliorates glucose intolerance and insulin resistance in HFD-induced obesity.** (A) Plasma glucose and (B) insulin levels were measured in fasting state. (C) HOMA-IR was calculated by using this formula:  $(FPI \times FPG) / 22.5$ . (D) IPGTT in 18-week-old C57BL/6 mice was performed by injecting 1 g glucose per kilogram body weight after 16 h fasting and (E) AUC of IPGTT was calculated. (F) IPITT was performed by injecting 0.75 IU insulin per kilogram body weight after 5 h fasting and (G) AUC of IPITT was calculated. (A–G) Values represent means  $\pm$  SE of seven mice per group. \* $p < 0.05$  versus ND, # $p < 0.05$  versus HFD. FPI, fasting plasma insulin concentration (mU/L); FPG, fasting plasma glucose (mmol/L); HOMA-IR, homeostatic model assessment for insulin resistance; IPITT, intraperitoneal insulin tolerance test.